A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.
| Autor: | Reeder, Craig B. 1, Reece, Donna E. 2, Kukreti, Vishal 3, Mikhael, Joseph R. 1, Chen, Christine 3, Trudel, Suzanne *, 3, Laumann, Kristina *, 4, Hentz, Joseph *, 5, Pirooz, Nick *, 1, Piza, Jg *, 3, Zepeda, Victor J Jimenez *, 1, Fonseca, Rafael *, 1, Bergsagel, P. Leif *, 1, Leis, Jose *, 1, Tiedemann, Rodger E. 1, Stewart, A. Keith 1 |
|---|---|
| Zdroj: | In Blood 20 November 2009 114(22):616-616 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|